We can’t show the full text here under this license. Use the link below to read it at the source.
Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction‐associated steatotic liver disease: Post hoc analysis of three randomised controlled trials
Similar weight loss with semaglutide in people with fatty liver disease, regardless of diabetes or heart and metabolism risk factors
AI simplified
Abstract
The overall mean weight change was -11.1 kg (-11.7%) with in adults with /MASH.
- Weight loss with semaglutide was significantly greater than with placebo, which resulted in a mean weight change of -0.7 kg (-0.6%).
- Individuals without type 2 diabetes experienced a numerically higher weight loss with semaglutide compared to those with type 2 diabetes or pre-type 2 diabetes.
- Estimated treatment differences for weight loss with semaglutide compared to placebo were similar across groups: type 2 diabetes (-10.2 kg), pre-type 2 diabetes (-9.8 kg), and no diabetes (-11.6 kg).
- No statistically significant differences in weight loss were observed between the diabetes status groups (p > 0.50 for all).
- Baseline metabolic parameters, including fasting plasma glucose and insulin levels, did not correlate with weight change.
AI simplified
Key numbers
-11.1 kg
Mean Weight Change with
Weight change at 1 year for group.
-0.7 kg
Mean Weight Change with Placebo
Weight change at 1 year for placebo group.
209 of 300
Participants with Type 2 Diabetes
Total participants with type 2 diabetes in the study.